The UK’s Office of Fair Trading announced the referral of the completed buyout of eye correction company Ultralase by competitor Optimax to the Competition Commission in what reports say suggests the OFT may have found cause of concern regarding the deal. The deal occurred in November of last year without informing the OFT; it was not until the companies’ merger was undeway that the regulator started probing the buyout. Reports say by the initiation of the review, several Ultralase clinics were already replaced by Optimax clinics. In its review, the OFT found six geographical areas whose competition was threatened by the deal. Reports say the Commission will reach a decision on the deal by January 12 of next year.
Full Content: OptometryToday
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI